Haleon (NYSE:HLN – Get Free Report) issued its quarterly earnings data on Thursday. The company reported $0.05 earnings per share for the quarter, Zacks reports. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion.
Haleon Trading Up 3.0 %
Shares of HLN traded up $0.30 during mid-day trading on Friday, reaching $10.09. 2,704,722 shares of the company’s stock traded hands, compared to its average volume of 10,134,119. The stock has a market cap of $45.66 billion, a P/E ratio of 29.63, a P/E/G ratio of 2.82 and a beta of 0.28. The stock’s 50-day moving average is $9.59 and its two-hundred day moving average is $9.83. Haleon has a 12 month low of $7.89 and a 12 month high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on HLN shares. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.95.
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Read More
- Five stocks we like better than Haleon
- What is the MACD Indicator and How to Use it in Your Trading
- 5 Best Gold ETFs for March to Curb Recession Fears
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why Smart Investors Are Watching These 3 Undervalued Stocks
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.